Although not statistically different than CD133− cell populations (p = 0.29), the tumor-initiating potential of cells enriched for CD133 is well documented in multiple studies from malignancies from various organ systems, including pancreatic cancer. This evidence concerns the gene PROM1 and pancreatic neoplasm.